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Abstract (153/250 words) 25 
The genetically heterogeneous Spinocerebellar ataxias (SCAs) are caused by 26 
Purkinje neuron dysfunction and degeneration, but their underlying pathological 27 
mechanisms remain elusive. The Src family of non-receptor tyrosine kinases (SFK) are 28 
essential for nervous system homeostasis and are increasingly implicated in 29 
degenerative disease.  Here we reveal that the SFK suppressor Missing-in-Metastasis 30 
(MTSS1) is an ataxia locus that links multiple SCAs. MTSS1 loss results in increased 31 
SFK activity, reduced Purkinje neuron arborization, and low basal firing rates, followed 32 
by cell death. Surprisingly, mouse models for SCA1, SCA2, and SCA5 show elevated 33 
SFK activity, with SCA1 and SCA2 displaying dramatically reduced MTSS1 protein 34 
levels through reduced gene expression and protein translation, respectively. Treatment 35 
of each SCA model with a clinically-approved Src inhibitor corrects Purkinje basal firing, 36 
and delays ataxia progression in MTSS1 mutants. Our results identify a common SCA 37 
therapeutic target and demonstrate a key role for MTSS1/SFK in Purkinje neuron 38 
survival and ataxia progression. 39 
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Significance Statement (120/120) 61 
The Src family of non-receptor tyrosine kinases (SFK) are essential for nervous system 62 
function, and may contribute to neurodegeneration. Spinocerebellar ataxias (SCAs) are 63 
neurodegenerative diseases where Purkinje neurons fire irregularly and degenerate 64 
leading to motor problems. We show that the SFK suppressor Missing-in-Metastasis 65 
(MTSS1) is an ataxia gene that links multiple SCAs. MTSS1 loss results in increased 66 
SFK activity, degenerating Purkinje neurons with low firing rates, and cell death. 67 
Surprisingly, mouse models for three different SCAs show elevated SFK activity, with 68 
SCA1 and SCA2 models displaying dramatically reduced MTSS1 protein levels. 69 
Treatment of each SCA model with SFK inhibitor corrects Purkinje basal firing, and 70 
delays ataxia progression in MTSS1 mutants. Our results identify a common link among 71 
disparate neurodegenerative diseases. 72 
 73 
  74 
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Introduction 76 
Neurons are non-dividing cells that depend on homeostatic regulation of protein, 77 
RNA, and metabolite turnover to permit dynamic synaptic connections that allow 78 
adaptation to changing environments. Loss of such mechanisms result in one of several 79 
hundred neurodegenerative disorders.  Over 40 loci form the genetic basis for human 80 
Spinocerebellar Ataxia (SCA), a progressive motor disorder characterized by cerebellar 81 
atrophy and pervasive Purkinje neuron degeneration where patients experience poor 82 
coordination and balance, hand-eye coordination, dysarthria, and abnormal saccades. 83 
 One common phenotype prominent in multiple SCA animal models is the altered 84 
Purkinje neuron firing rates that precede motor impairment and cell death (1-3), with 85 
restoration of the normal firing rates reducing Purkinje neuron death and improving 86 
motor function (4, 5).  Defects in many cell functions lead to SCA including effectors of 87 
transcription (6), translation (7), proteostasis (8, 9), calcium flux (10, 11), and 88 
cytoskeletal/membrane interactions (12, 13). An open question remains how the many 89 
SCA genes interact to control firing rates and cell survival, with a common target 90 
emerging as an ideal treatment for the genetically diverse etiologies. 91 
One such therapeutic target is the class of Src family of non-receptor tyrosine kinases 92 
(SFKs). Several SFKs are expressed in the nervous system and have partially 93 
overlapping functions. While single mutants for Src or Yes kinase have no overt 94 
neuronal phenotype (14, 15), Fyn loss of function leads to increased Src activity and 95 
hippocampal learning and memory deficits (16, 17)  Moreover, Fyn;Src double mutants 96 
rarely survive past birth and have severely disorganized cortical and cerebellar layers 97 
(15, 18). SFKs are post-translationally regulated through activating and inhibitory 98 
phosphorylation marks deposited by inhibitory kinases and removed by receptor tyrosine 99 
phosphatases in a context dependent manner (19, 20). SFK activation occurs rapidly in 100 
response to extracellular signals and in response to a variety of cellular stresses ranging 101 
from osmotic pressure (21) to tetanic stimulation (22). Additionally, SFKs are 102 
inappropriately active in disease states including Amyotrophic lateral sclerosis (23), 103 
Alzheimer disease (24), and Duchenne muscular dystrophy (25).  104 
 Missing-in-Metastasis (MTSS1) is one of the defining members of the I-BAR 105 
family of negative membrane curvature sensing proteins first identified as being deleted 106 
in metastatic bladder cancer (26). Although MTSS1 biochemically interacts with 107 
membranes and regulates the actin cytoskeleton (27), genetic studies reveal that 108 
MTSS1 functions in an evolutionarily conserved signaling cassette to antagonize Src 109 
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kinase activity (28, 29).  Disruption of the MTSS1/Src regulatory cassette results in 110 
endocytosis and polarization abnormalities demonstrated by defects in primary cilia 111 
dependent hedgehog signaling, and hair follicle epithelial migration (28). In tissues 112 
requiring MTSS1 function, levels of active MTSS1 are critical, as loss (26) or gain (30) of 113 
MTSS1 has been associated with metastasis and invasion. Regardless of the particular 114 
phenotype, an evolutionarily conserved property of MTSS1 mutants is that loss of 115 
MTSS1 function can be reversed through the removal or inhibition of Src kinases. This 116 
property was first demonstrated through double mutant analysis in the fly ovary, and 117 
subsequently in mammalian tissue culture using Src family kinase inhibitors (28, 29).  118 
The availability of FDA-approved Src kinase inhibitors has led to the investigation of 119 
clinically relevant MTSS1 phenotypes with the hope of using SFK inhibitors to ameliorate 120 
them.    121 
Although SFKs have been shown to regulate multiple classes of neurotransmitter 122 
receptors (31) they also function to control basic cytoskeletal components. Src regulates 123 
local actin polymerization (32) and endocytic receptor internalization (32-35). 124 
The actin cytoskeleton plays a critical role in cell signaling, proliferation, motility, and 125 
survival.  Local, rather than global, actin dynamics control homeostatic synaptic 126 
signaling, and abnormalities in actin regulation underlie a diversity of psychiatric and 127 
neuronal diseases including Amyotrophic lateral sclerosis (36), Schizophrenia, Autism 128 
Spectrum Disorders (37), and motor dysfunction such as spinocerebellar ataxia (SCA) 129 
(38).  A major challenge remains to understand how actin cytoskeletal regulation 130 
controls synaptic function and to develop improved therapeutics for these common and 131 
poorly-treated diseases.  132 
Here we reveal that actin regulator and SFK antagonist Mtss1 is an ataxia locus 133 
regulated by multiple SCA alleles that subsequently result in SFK hyper-activation.  We 134 
show that clinically-available Src inhibitors correct Purkinje neuron firing rates and delay 135 
ataxia progression, demonstrating a novel and druggable role for the evolutionarily 136 
conserved MTSS1/SFK network in Purkinje neuron survival and ataxia progression. 137 
 138 
Results 139 
Mtss1 null mice display a progressive ataxia 140 
Mtss1 functions in many tissues, and previous mutant alleles disrupting 5’ exons 141 
resulted in mild lymphmagenesis (39), progressive kidney disease (40), mild 142 
neurological phenotypes (41) and cerebellar dysfunction(42).  However, Mtss1 has 143 
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several possible internal promoters (43), and multiple splice variants with differing sub-144 
cellular localization (44), and existing mutant lines display MTSS1 proteins (40, 45). As 145 
an alternative approach we generated a conditional mutant allele targeting the 146 
endophilin/Src interacting domain located in the final exon (MIMEx15, Fig 1A) (28, 29). 147 
Germline deletion with HPRT-cre resulted in the loss of MTSS1 protein as detected by 148 
an antibody specific to the N-terminal IMD domain (30) (Fig 1B).  149 
To our surprise, homozygous MIMEX15 mutants appear normal for cilia dependent 150 
processes with no observed instances of holoprosencephaly or polydactyly after multiple 151 
generations. Additionally, MIMEX15 mutant males are fertile. Instead, MIMEX15 mutants 152 
display a striking and progressive ataxia.  To better understand the nature of MIMEX15 153 
ataxia, we characterized MIMEX15 mutants using an open field test to evaluate gross 154 
motor control. MIMEX15 mutants had reduced velocity (Fig 1C) and rearing behavior (Fig 155 
1D), consistent with overall movement defects. To uncouple possible motor and 156 
behavioral abnormalities we evaluated MIMEX15 mutants with rotarod assay and 157 
observed coordination abnormalities in as early as 4 weeks of age (Fig 1E). Many 158 
spinocerebellar ataxias display progressive neurologic phenotypes. To determine 159 
whether MIMEX15 animals showed progressive deterioration we employed a composite 160 
test measuring gait, grip strength and balance (46). We found MIMEX15 animals 161 
performed consistently worse than controls, with severity increasing with age (Fig 1F). 162 
MIMEX15 heterozygous animals displayed 75% of normal protein levels (SI Appendix, Fig 163 
S1C), giving no overt phenotype. 164 
 Reduced Mtss1 levels are associated with a variety of cellular phenotypes 165 
including reduced presentation of receptors on the cell membrane (47), and altered 166 
Purkinje neuron morphology (41, 44). To determine the basis of the motor abnormalities 167 
and to distinguish among these possibilities we performed histological analysis. At 4 168 
weeks, MIMEX15 mice are ataxic, yet their cerebella appeared grossly normal with intact 169 
granule, Purkinje neuron, and molecular layers. However, MIMEX15 mutants displayed a 170 
progressive loss of Purkinje neurons in all cerebellar lobes readily seen by 8 weeks of 171 
age (Fig S1A). Whereas wild type cerebella contain approximately 8 Purkinje neurons in 172 
a 250 μm linear distance, 8-week old mice retained only 25% of wild type, and 36 week 173 
MIMEX15 mutants contained only 5% of the total number of Purkinje neurons (Fig 1G).  174 
While ataxia genes can act in many cell types to regulate Purkinje cell function, 175 
MTSS1 is highly expressed in Purkinje cells, suggesting it is required in these cells for 176 
normal Purkinje cell function and survival.  To confirm the Purkinje neuron defects seen 177 
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in MIMEX15 animals are due to a cell autonomous requirement for Mtss1, we conditionally 178 
inactivated Mtss1 using the Purkinje neuron specific L7-Cre (MIMcko) then compared 179 
Purkinje neuron morphology and loss to the global MIMEX15 mutant. MIMcko Purkinje 180 
neurons were mosaic for MTSS1 expression likely due to inefficient LoxP recombination 181 
as the MTSS1 antibody showed high specificity (SI Appendix Fig S1B). At 20 weeks 182 
MIMcko had a significant reduction in Purkinje neurons. In remaining Purkinje neurons, 183 
those lacking MTSS1 protein displayed thickened dendritic branches and reduced arbor 184 
volume, while neighboring Purkinje neurons with MTSS1 protein appeared normal (Fig 185 
1H). We conclude that Mtss1 acts cell autonomously in Purkinje neurons to maintain 186 
dendritic structure, with loss of MTSS1 resulting in abnormalities and eventual cell death. 187 
 188 
Mtss1 mutant neurons display limited autophagic markers 189 
 An emergent mechanism of cell loss during neurodegeneration is aberrant 190 
macroautophagy. Autophagy is essential for Purkinje neuron survival, as loss of 191 
autophagy (48, 49) results in cell death. Increased levels of early autophagy markers 192 
have been described in multiple neurodegenerative diseases including Huntington’s 193 
disease (50), Alzheimer disease (51), and SCA3 (52). MIMEX15 mutants partially fit this 194 
pattern of disease as we observed some signs of autophagy. As early as 4 weeks, we 195 
observed increased Complex V/ATP synthase staining indicative of fused mitochondria 196 
as well as dramatically reduced staining for the Golgi body marker Giantin (Fig 2A). We 197 
also observed increased transcript abundance for the early autophagy effector VMP1 198 
(53). By 8 weeks of age we could detect increased LC3-II species (Fig 2B, SI Appendix 199 
S2A), and electron microscopy revealed several autophagy related morphologies 200 
including swollen mitochondria, fragmented golgi bodies, lamellar bodies and double 201 
membrane autophagic vacuoles (Fig S2C). Interestingly, we were unable to detect 202 
increased Sqstrm1 (p62) transcript or protein levels in MIMEX15, an autophagocytic 203 
adapter protein associated with protein aggregation neurodegenerative disease (54) (Fig 204 
S2B). MIMEX15 animals displayed increased neuroinflammation shown by increased Aif1 205 
transcript levels (Fig 2D), a readout of microglial infiltration. MIMEX15 animals also show 206 
increased GFAP positive glial infiltration (Fig 2E, 2F, SI Appendix S1A) consistent with 207 
reactive astroglyosis. Consistent with signs of autophagocytic cell death and 208 
neuroinflammation, we failed to see increased DNA breaks in MIMEX15 Purkinje neurons 209 
with TUNEL stain (Fig 2G). 210 
 211 
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Mtss1 prevents SFK dependent Purkinje neuron firing defects and ataxia 212 
To characterize cellular changes associated with the ataxia present in 4-week old 213 
MIMEX15 mice, we examined the dendritic tree of individual biocytin injected Purkinje 214 
neurons (Fig 3A). Purkinje neuron dendritic arbor collapse has been observed in several 215 
SCA models including SCA1 (2), SCA5 (3), while many other models have shown 216 
thinned molecular layer including SCA2(1), SCA3 (55), that likely reflects reduced 217 
Purkinje dendritic volume. Similarly, MIMEX15 mutants showed a 60% reduction in the 218 
expansiveness of the dendritic tree (Fig 3B) and a significant decrease in the number of 219 
dendritic spines (Fig 3C), although no significant difference was detected in spine length 220 
(Fig 3D) or width (Fig 3E).  221 
 In dermal fibroblasts and Drosophila border cells MTSS1 functions to locally 222 
prevent ectopic Src kinase activity and Mtss1 mutant phenotypes can be rescued by 223 
genetically removing Src kinase (28, 29). To determine if Mtss1 acts similarly in Purkinje 224 
neurons we evaluated SFK activity levels in cerebellar lysates from MIMEX15 mutants and 225 
found elevated levels of SFKY416 (Fig 3F) indicative of increased SFK activity. Previous 226 
work has shown strong functional interactions between SFK and metabotropic glutamate 227 
receptor type I (mGluR1) neurotransmission at parallel fiber synapse (56). To investigate 228 
whether MTSS1/SFK modulation of mGluR1 signaling forms the basis of the ataxia, we 229 
performed electrophysiological analysis of Purkinje neurons in cerebellar slices from 230 
MIMEX15 mice. We evaluated Purkinje neuron response to parallel fiber stimulation using 231 
calcium imaging. We found MIMEX15 mutant Purkinje neurons responded with a 232 
comparable increase of calcium dependent fluorescence to controls, while adding the 233 
mGluR1 antagonist CPCCOEt abolished these responses (Fig 3G). These data support 234 
MTSS1 acting post-synaptically to control Purkinje cell function. 235 
 Purkinje neurons maintain a cell autonomous tonic firing rate that is essential for 236 
their function (57, 58). Since MIMEX15 Purkinje neurons responded normally to parallel 237 
fiber stimulation suggesting normal synaptic transmission, we assayed basal firing rate. 238 
Purkinje neuron tonic firing rate is highly sensitive to temperature and may vary slightly 239 
between investigators (59). In our assays, wild type cells had a mean firing rate of 240 
43±2Hz (n=2 animals, 62 cells), while 4-week old MIMEX15 mutants exhibited a 12±1Hz 241 
mean rate (n=2 animals, 55 cells) (Figs 3H, 3I). Previous studies of SCA mouse models 242 
demonstrated reduced tonic firing is a basis for ataxia (1, 3, 5). Since basal firing is 243 
reduced at an age when MIMEX15 mice possess a normal number of Purkinje neurons, our 244 
results suggest neuron malfunction rather than loss underlies the initial ataxia phenotype.  245 
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 MTSS1/Src double mutants rescue MTSS1 phenotypes in Drosophila and 246 
vertebrate cell culture. To test the hypothesis that reducing SFK activity would 247 
ameliorate the MIMEX15 ataxia phenotype, we added the FDA-approved SFK inhibitor 248 
dasatinib to cerebellar slice preparations and measured basal firing rate, using a 249 
concentration approximately 2-fold over in vivo IC50 (200nM, Fig 3H, 3I). Dasatinib 250 
significantly increased the MIMEX15 basal firing rate from baseline to 29±1Hz (n=2 251 
animals, 62 cells). We also observed that dasatinib slightly reduced the wild type basal 252 
firing rate to 35±1Hz (n=2 animals, 79 cells). Time course experiments showed the 253 
increase in basal firing rate occurred over 5 hours (SI Appendix Fig S3), consistent with 254 
a low concentration, high affinity mechanism of action. Direct modulation of ion channel 255 
or mGluR1 activity raises basal firing within minutes (4, 60), suggesting that dasatinib 256 
works through a distinct mechanism. To determine whether SFK inhibition ameliorates 257 
ataxia in vivo we administered dasatinib directly to the cerebellum via minipumps to 258 
overcome poor CNS bioavailability (61). Over 4 weeks, dasatinib treated MIMEX15 mice 259 
were protected from disease progression while untreated mice showed progressively 260 
worsening rotarod performance (Fig 3J) (n=2 drug, 3 control). These results 261 
demonstrate that Src family kinases act downstream of MTSS1 and that SFK inhibitors 262 
rescue Mtss1-dependent basal firing rate defects to slow disease progression.  263 
 264 
Mtss1 is a translation target of ATXN2 265 
The slow basal firing and ataxia preceding cell death seen in the MIMEX15 266 
mutants resembles that seen in other SCA models such as SCA1, SCA2, and SCA5, 267 
prompting us to investigate whether MTSS1/SFK dysregulation occurs in other ataxias. 268 
SCA2 is caused by an expansion in the polyglutamine (polyQ) tract of the RNA binding 269 
protein ATAXIN-2 (ATXN2) to more than 34 repeats (62). The exact molecular defects 270 
that drive SCA2 pathogenesis remain unclear, as loss of function mice do not 271 
recapitulate the SCA2 phenotype (63), while intermediate expansion alleles are 272 
associated with increased risk for frontotemporal dementia (64). Atxn2 has an ancestral 273 
role in translation control (7, 65), which may be altered with the SCA2 mutation, but the 274 
exact targets have yet to be described.  275 
 MTSS1 protein abundance is heavily regulated by metastasis-associated miRs 276 
which bind to the Mtss1 3’ untranslated region and reduce steady-state MTSS1 protein 277 
levels (66-70) To determine whether MTSS1 protein accumulation is sensitive to Atxn2 278 
we examined the ATXN2Q127mouse model of SCA2 (1). We found MTSS1 abundance 279 
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was progressively reduced by 90% at 24 weeks, a level far greater than the 50% 280 
reduction in Purkinje neuron marker Calbindin (Fig 4A upper band, SI Appendix Fig 281 
S4). Cerebellar SFK activity was increased nearly 8-fold in ATXN2Q127 animals compared 282 
to wild type littermates (Fig 4B).  283 
 We sought to determine whether the age-dependent reduction in Purkinje neuron 284 
basal firing frequency seen in ATXN2Q127mice is due to elevated SFK activity. 285 
Remarkably, addition of dasatinib to ATXN2Q127 cerebellar slices restored the basal firing 286 
rate from an average of 14±1Hz (n=2 animals, 100 cells) to nearly normal levels of 287 
32±2Hz (n=2 animals, 72 cells; Fig 4C, 4D).  As in the MIMEX15 mutants, the firing rate 288 
reached maximal effect at 5-6 hours of SFK inhibition (SI Appendix Fig S3), leading us 289 
to conclude that inappropriate SFK activity underlies both the ATXN2 and MTSS1-290 
mediated firing phenotype.  291 
 The convergence of Mtss1 and ATXN2 on SFK activity suggested they work in a 292 
common or parallel molecular pathway. To distinguish between these possibilities, we 293 
further interrogated MTSS1 protein levels in ATXN2Q127 cerebella. While we found  294 
reduction of MTSS1 protein (Fig S4A) and RNA in ATXN2Q127 Purkinje neurons (Fig 295 
S4B) , we failed to see comparable changes in ATXN2 levels in 4-week old MIMEX15 296 
mice (Fig 4E). Because ATXN2 possesses RNA binding activity, and Mtss1 contains a 297 
long 3’UTR, we hypothesized that ATXN2 controls Mtss1 translation in Purkinje neurons. 298 
RNA-IP followed by QPCR in cells expressing  tagged versions of either WT (ATXNQ22) 299 
or SCA2 (ATXN2Q108) demonstrated both proteins specifically bound MTSS1 mRNA 300 
compared to GAPDH control. (Fig 4F). Using a luciferase reported fused to the MTSS1 301 
3’ UTR we were able to map the ATXN2 interacting domain to a central 500bp region 302 
that was sufficient for both RNA-protein interaction and translation control (SI Appendix 303 
Fig S4C,D). Furthermore, polyribosome fractionation experiments revealed that 304 
pathogenic ATXN2Q108 was sufficient to block the translation of reporter mRNA fused to 305 
the MTSS1 3’UTR shifting the transcript from the polyribosome fractions to a detergent 306 
resistant fraction consistent with stress granules (Fig 4G).  These results suggest the 307 
pathogenic ATXN2 acts directly as a dominant negative RNA binding protein preventing 308 
MTSS1 translation. Notably, we observed MTSS1 abundance is reduced in human SCA 309 
patient cerebellum, bolstering the evolutionary conservation of the ATXN2/MTSS1 310 
interaction (Fig 4H).  311 
 312 
SFK inhibition rescues Purkinje neuron firing across SCA 313 
MTSS1/SFK Ataxia  
 
11 of 32  
 Two other SCA mouse models have been shown to have slow basal firing rates, 314 
SCA1 (2) and SCA5 (3). Much like SCA2, SCA1 is due to a polyQ expansion in the RNA 315 
binding protein ATAXIN-1 (ATXN1)(71). One observed result of the SCA1 allele is 316 
changed ATXN1 association with transcriptional regulatory complexes (72), leading to 317 
vastly different Purkinje neuron mRNA profiles (73). However, the exact targets that 318 
drive SCA1 pathogenesis are still being determined. Unlike SCA1 and SCA2, SCA5 is a 319 
more pure cerebellar ataxia due to lesions in the structural protein β-III spectrin (13). β-III 320 
spectrin directly binds to and controls the cell membrane localization of EAAT4 321 
(excitatory amino acid transporter 4), a protein involved in the synaptic clearance of 322 
glutamate (12, 74). 323 
If SCA1 or SCA5 arises similarly to SCA2 by dysregulation of the MTSS1/SFK 324 
cassette, we would expect decreased MTSS1 abundance. Indeed, in the ATXN1Q82 325 
mouse model of SCA1 (75) we observed a 95% decrease in MTSS1 protein abundance 326 
(Fig 5A) with only a 50% reduction in calbindin, suggesting the loss of MTSS1 is not 327 
solely due to loss of Purkinje neurons. 328 
Atxn1 pathogenicity is partially driven by phosphorylation at serine 776 (72), 329 
which was unchanged in 4-week old MIMEX15 mice, suggesting MTSS1 is a target of the 330 
SCA1 allele (Fig 5B). Additionally, Mtss1 transcript abundance is reduced at multiple 331 
ages in ATXN1Q8 mice (73) (Fig 5C). We found treating ATXN1Q82 slices with dasatinib 332 
increased the basal firing rate from a baseline of 15±1Hz (n=3 animals, 21 cells) to 333 
23±2Hz (n=3 animals, 21 cells), a level statistically indistinguishable from dasatinib-334 
treated controls (Fig 5D).  335 
By contrast, the Sptbn2 knockout model of SCA5 (βIII-/-)(3), showed no change in 336 
MTSS1 protein abundance at 3 weeks yet demonstrated a clear increase in SFKY416 337 
phosphorylation (Fig 5E). We also observe increased basal firing from 25±1Hz (n=2 338 
animals, 31 cells) to 30±2Hz (n=3 animals, 43 cells) over a 7-hour period of dasatinib 339 
treatment (Fig 5F). We fail to see changes in β-III spectrin abundance in MIMEX15 mice, 340 
and detect a 40% decrease in β-III spectrin levels in 24-week ATXN2Q127 mice that is 341 
likely due to reduced Purkinje neuron dendritic arbor size, correlating with calbindin 342 
levels (Fig 5G, 5H). Together these data suggest that β-III spectrin and MTSS1 may 343 
work in parallel, through different mechanisms, to modulate SFK activity (Fig 5I).  344 
 345 
Discussion 346 
 While SCA gene functions appear heterogeneous, our study establishes a 347 
genetic framework to understand how several SCA loci regulate SFK activity to ensure 348 
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neuronal homeostasis and survival.  We identify β-III spectrin and MTSS1, proteins that 349 
link the cell membrane and actin cytoskeleton, as negative regulators of Src family 350 
kinases. We show that MTSS1 is a target of the SCA genes ATXN1 and ATXN2 (Fig 5I), 351 
and that increased SFK activity from lesions in MTSS1, SPTNB2 (SCA5), 352 
ATXN1(SCA1), and ATXN2 (SCA2) reduces Purkinje neuron basal firing, an 353 
endophenotype that underlies multiple ataxias, providing support for the clinical use of 354 
SFK inhibitors in many SCA patients. 355 
Our results reveal a central role for the MTSS1/SFK regulatory cassette in 356 
controlling neuronal homeostasis and survival.  MTSS1 regulation of SFKs has been 357 
demonstrated in several migratory cell types including metastatic breast cancer and 358 
Drosophila border cells. This is the first demonstration of the regulatory cassette 359 
functioning in non-migratory post-mitotic cells. MTSS1 integrates the cell membrane and 360 
cytoskeletal response to local signals by serving as a docking site for the kinases and 361 
phosphatases that control actin polymerization (76), a process essential for dendritic 362 
spine assembly, maintenance and function. In fly border cells, MTSS1-regulated SFK 363 
activity polarizes the membrane to spatially detect guidance cues. Similarly, MTSS1 364 
functions in neurons to promote dendritic arborization and spine formation, structures 365 
that were shown to be essential for maintaining basal firing frequencies by electrically 366 
isolating increasing areas of Purkinje neuron dendrites (59). Other members of the I-367 
BAR family of membrane/cytoskeletal signaling proteins have been implicated in human 368 
neurological disorders such as microcephaly (77), but it remains to be determined how 369 
they interact with MTSS1.  370 
 Disruption of post-transcriptional gene regulation leading to altered proteostasis 371 
has recently emerged as a key contributor to neurodegeneration. In the cerebellum, 372 
reducing the abundance of the RNA-binding protein Pumilio leads to SCA1-like 373 
neurodegeneration through a specific increase in ATXN1 protein levels (78, 79). Yet 374 
Pumillio binds hundreds of transcripts to control protein levels (80, 81), suggesting that 375 
changing protein abundance of a few key effector genes post-transcriptionally leads to 376 
disease. Our data demonstrate that MTSS1 is a key effector gene whose activity is 377 
tightly regulated to prevent Purkinje neuron malfunction.  Post-transcriptional control of 378 
MTSS1 is disrupted in many disease states such as cancer, where MTSS1 levels are 379 
reduced by locus deletion or miRNA overexpression and are associated with increased 380 
metastasis and poorer prognosis (67, 82).  In Purkinje neurons, the SCA1 ATXN1Q82 381 
allele reduces MTSS1 transcript levels.  ATXN1 is thought to act as a transcriptional 382 
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regulator by associating with the transcriptional repressor Capicua (CIC) (72), though it 383 
remains to be shown whether the ATXN1/CIC complex occupies the MTSS1 promoter. 384 
By contrast, the SCA2 allele ATXN2Q58 binds the MTSS1 3’ UTR to prevent ribosome 385 
binding and MTSS1 translation, ultimately leading to increased SFK activity. ATXN2 386 
(and the redundant gene ATXN2L) have recently been identified in a large complex of 3’ 387 
UTR binding proteins that regulate networks of genes controlling epithelial differentiation 388 
and homeostasis (83). Our results suggest other ataxia disease genes that control 389 
proteostasis may also regulate MTSS1 abundance, and the strong role for miRNAs 390 
controlling MTSS1 abundance in cancer suggest they may also function as effectors of 391 
as yet undescribed ataxia loci.  392 
The identification of the MTSS1/SFK regulatory cassette in multiple ataxias 393 
further reinforces the pathological consequences associated with inappropriate SFK 394 
activation in response to a variety of cellular stresses. While the cytoskeletal regulator 395 
MTSS1 is an evolutionarily-conserved SFK inhibitor, SFK effects on Purkinje neuron 396 
basal firing may derive from the fundamental roles SFKs play in cell homeostasis outside 397 
cytoskeletal control. For example, SFK control of translation is implicated in Alzheimer 398 
disease, as reducing SFK activity proves beneficial for Alzheimer disease progression 399 
(24)  due to SFK control of  pathogenic Aβ translation (84). SFK impairment of 400 
autophagy is seen in models of Amyotrophic lateral sclerosis and Duchenne muscular 401 
dystrophy (23, 85). Additionally, reduction of Src kinase expression was identified as a 402 
suppressor of SCA1 toxicity in Drosophila ommatidia (86), supporting the need for 403 
moderating SFK activity.  The pleiotropic effects of inappropriate SFK activity suggest 404 
that SFK inhibition may be a critical therapeutic node to slow the progression of multiple 405 
neurodegenerative disorders including SCAs. Our work points out the need for future 406 
development of neuro-active SFK inhibitor variants, as currently approved Src inhibitors 407 
were designed for oncology targets and lack potent central nervous system activity.   408 
Further, while we provide data for kinase inhibition to suppress MTSS1 loss, we have 409 
previously shown that SFK regulation by regulatory receptor tyrosine phosphatases, or 410 
deletion of endocytic adapter proteins can also revert the effects of MTSS1 loss. Given 411 
the challenge of developing specific kinase inhibitors, our work opens additional 412 
therapeutic classes to alleviate the progression of neurodegenerative diseases.   413 
In summary, the identification of Mtss1 as a novel recessive ataxia locus extends 414 
the physiologic functions requiring the MTSS1/SFK signaling cassette, which include cell 415 
polarity, migration, and cancer metastasis. Each of these disparate processes highlight 416 
MTSS1/SFK Ataxia  
 
14 of 32  
the common role MTSS1 plays integrating the cell membrane and cytoskeletal response 417 
to local signals, as the dendritic spine defects seen in MIMEX15-mutant Purkinje neurons 418 
(Fig 3A-E) recalls the loss of directional cell extensions in migrating Drosophila border 419 
cells (29). They also reinforce the critical need to suppress inappropriate SFK activity, 420 
and provide a therapeutic opportunity for otherwise devastating and debilitating 421 
diseases.  422 
 423 
Materials and Methods 424 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  425 
Generation of MIMEX15 allele: 426 
To generate the MIMEX15 conditional allele exon15 was cloned into the PGK-gb2 targeting 427 
vector between the 5’ LoxP site and the 3’ LoxP/FRT flanking neomycin cassette. The 428 
targeting vector contained a 5.97kb 5’ homology arm that included exons 12, 13, 14 and 429 
a 2.34kb 3’ homology arm that included the 3’-UTR. The targeting vector was 430 
electroporated into C57bl6xSV129 embryonic stem cells, and Neo-resistant colonies 431 
were screened by PCR. Chimeric mice were generated by injecting ES cells into 432 
blastocysts, and chimeras were mated to a FLP deleter strain(87). To generate MIMEX15 433 
null animals, mice with the MIMEX15 conditional allele were crossed to HPRT-Cre 434 
mice(88). Mice were maintained on a mixed C57bl6 SV129 background and examined at 435 
listed ages. 436 
 437 
MIMCKO: MIM EX15Loxp mice were crossed to L7-Cre (89) to generate MIMCKO. 438 
 439 
ATXN2Q127: ATXN2Q127 mice were previously characterized in (1). 440 
 441 
ATXN1Q82: ATXN1Q82 mice were previously characterized in (75). 442 
 443 
SPTNB2: SPTNB2 null mice were previously characterized in (3). 444 
METHOD DETAILS  445 
Behavior testing: 446 
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Rotarod and activity chamber testing was performed by the Stanford Behavioral and 447 
Functional Neuroscience Lab. For rotarod mice were trained on 2-20rpm accelerating rod 448 
for 4 trials with 15 minute rest intervals between trials. Testing was performed after one 449 
rest day at 16rpm constant speed. For activity chamber mice were placed in chamber and 450 
measured for 10 minutes 3 times on separate days.  451 
 452 
Composite Limb Gait Ledge test was performed as in (46).  453 
 454 
Cerebellar dasatinib administration: 455 
Mice were trained on 4-40rpm accelerating rotorod with 15 minute rest intervals. Mice 456 
were tested on the same 4-40rpm paradigm after a rest day. 457 
Dasatinib was dissolved in 40% capitsol to a 9mM solution, then diluted in acsf and 458 
loaded into azlet pump 1004. Cannulas were inserted at midline, -6.2mm cadual -2.5 DV 459 
from bregma. Sutures were closed with ethilon and mice were allowed to recover before 460 
subsequent rotarod tests. 461 
 462 
Western blot:  463 
Isolated tissues were lysed in RIPA buffer supplemented with complete mini protease 464 
inhibitor (Roche) and PhosStop (Roche). Protein concentrations were normalized by 465 
using the BCA assay (Pierce). Proteins were electrophoresed on Novex 4-12%, 3-8%, 466 
10-20% gradient gels or 16% gels. Rabbit anti-Src-Y416 (CST 2101S or CST 6943S), 467 
mouse anti-beta actin (Sigma), rabbit anti-Sptbn2 (Thermo PA1-46007), rabbit anti-Atxn2 468 
(Sigma HPA021146), mouse anti-Atxn1 (abcam ab63376), rabbit anti-LC3A/B (CST 469 
4108), rabbit anti-P62 (CST 23214) rabbit anti-Src (CST 2123 or CST 2108), primary 470 
antibodies were detected with LICOR secondary antibodies. 471 
 472 
Quantitative RT-PCR (QPCR): 473 
QPCR was performed on Trizol extracted total RNA from 3-5 animals per condition using 474 
RNA to Ct reagent with the following probes: Mm00479862_g1 (Aif1), Mm00448091_m1 475 
(Sqstrm1), Mm00774656_m1 (Vmp1), Mm99999915_g1 (Gapdh). Fold enrichment was 476 
calculated using 2[-ΔΔCt].477 
 478 
 Antibodies and Immunofluorescence:  479 
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Isolated cerebella were immersion fixed in 4% paraformaldehyde and embedded in 480 
paraffin. 7μm sections were cut and deparaffinized using standard conditions before 481 
staining. Sections were blocked with 20% horse serum 0.3% Triton X-100 in PBS. The 482 
following antibodies were used at 1:1000 dilutions: 483 
Rabbit anti-Mtss1(30), Rabbit anti-Calbindin (CST 13176), mouse anti-Calbindin-D-28K 484 
monclonal (Sigma), mouse anti-Complex V (Novex 459240), rabbit anti-Ubiquitin (CST 485 
3933), rabbit anti-Giantin (Abcam ab 24586), Chicken anti-GFAP (Abcam ab4674).  486 
Alexafluor conjugated secondary antibodies were purchased from Invitrogen. Images 487 
were acquired either on a Leica SP2 AOBS laser scanning microscope or a Zeiss 488 
axioplan widefield scope.  489 
 490 
Human samples: 491 
Paraffin-embedded brain slices from SCA2 patient were provided by Prof. Arnulf H. 492 
Koeppen, M.D., Albany Medical College, New York, USA. Non-SCA2 control paraffin-493 
embedded brain slices were provided by Dr. Sonnen, Pathologist, University of Utah. 494 
Human tissues were maintained and processed under standard conditions consistent 495 
with National Institutes of Health guidelines and conformed to an approved University of 496 
Utah IRB protocol. Sections were deparaffinized using standard conditions and 497 
blocked/permeabilized with 5% donkey serum 0.3% Triton X-100 in PBS and processed 498 
for immunostaining. The nuclei were stained with DAPI followed by mounting with 499 
Fluoromount-G (Southern Biotech, Cat# 0100-01). Antibody dilutions for tissue 500 
immunostainings were custom-designed MTSS1 antibody (1: 500) and fluorescent 501 
secondary antibody: goat anti-rabbit IgG (H+L) antibody, DyLight-488 [(1:1,000) 502 
(ThermoFisher Scientific, Cat# 35552)]. Images were acquired using confocal 503 
microscope (Nikon Eclipse Ti microscopy) in University of Utah cell imaging core lab, 504 
and analyzed by NIS-Elements AR 4.5 software. As massive degeneration of cerebellum 505 
is seen in SCA2 brain tissue, the lobe can’t be verifiable.   506 
 507 
TUNEL assay:  508 
Tunel assay was performed using NeuroTACS in situe apoptosis detection kit (R&D 509 
systems) according to manufacturer instructions. 510 
 511 
Luciferase assay: 512 
MTSS1/SFK Ataxia  
 
17 of 32  
Luciferase activity was measured using Mtss1 UTR clone S811096 from Switchgear 513 
genomics. Constructs were transfected into 293T cells using FugeneHD 48 hours before 514 
measurement. For each well of a 96 well plate, 20ng reporter vector was transfected with 515 
reported concentration of ATXN2-Q22-flag or ATXN2-Q108-flag constructs. PCDNA was 516 
used to normalize transfection amounts. 517 
Luciferase activity was measured on Molecular Dynamics M5 with 1500ms 518 
integration time. Nested deletions were constructed by restriction digest, T4 blunting and 519 
ligation. Minimal constructs were generated by Gibson assembly.  520 
 521 
293 RNA-IP:  522 
RNA-IP for ATXN2 bound Mtss1 transcripts in human HEK-293 cells expressing Flag-tagged 523 
ATXN2 constructs was performed as in(7).  524 
 525 
MIM 3’UTR RNA-IP: 526 
293T Cells were lysed in 20mM Tris Ph 7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 1% 527 
Triton X-100, 20mM DTT supplemented with 20U/ml Superase inhibitor (Life), 2U/ml 528 
DNAse1 (NEB),  Complete ultra protease inhibitor tablets (Roche). Flag constructs were 529 
immunoprecipitated using Anti-Flag agarose beads (Sigma). RNA was isolated using 530 
Trizol (Life) and treated with DNAse1 (NEB) for 30 minutes. QRTPCR was performed 531 
with Taqman RNA to Ct  mastermix (Thermo) using the following custom probes (IDT) to 532 
determine RNA abundance (Luciferase) and plasmid contamination (Bacterial ORI).  533 
Luciferase: 534 
Probe: 5’ FAM-CAGCGACGA/zen/CCTGCCTAAGATGTT-IABkFQ  535 
Primer 1: 5’ CACGATAGCGTTGCTGAAGA  536 
Primer 2: 5’ CAGATCGTCCGGAACTACAAC 537 
Bacterial ORI: 538 
Probe: 5’ HEX-TTGAAGTGG/zen/TGGCCTAACTACGGC-IABkFQ 539 
Primer 1: 5’ GCAGAGCGCAGATACCAAATA 540 
Primer 2: 5’ CAGCCACTGGTAACAGGATTA 541 
 542 
Fractionation: 543 
3 10cm plates of 293T cells were transfected with 1ug Mtss1 UTR Luciferase, 3ug Atxn2 544 
48 hours before fractionation. 1 hour before harvest, media was changed on cells. 545 
Ribosomes were stalled by treating cells with 100ug/ml cycloheximide 5 minutes before 546 
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harvest. Cells were scraped into lysis buffer: 200U/ml Superase, 20mM DTT, 1%Triton-X 547 
100, 20mM Tris pH 7.5, 100mM KCl, 5mM MgCl2,100ug/ml cycloheximide, roche 548 
complete mini protease inhibitor tablet, pelleted by centrifuging 8000g 5 minutes. Lysate 549 
was normalized by UV 254 absorbance and loaded onto 10%-50% linear sucrose 550 
gradients. Gradients were centrifuged 2hrs at 35000rpm in a SW41 rotor. 14 fractions 551 
were collected from each gradient using a FoxyR1 collector, and UV254 traces were 552 
acquired. For RNA isolation, fractions were treated with TrizolLS (Life), followed by 553 
DNAse treatment and QRT-PCR. 554 
 555 
Electrophysiology: 556 
Preparation of Cerebellar Slices (SCA2 and Mtss1) 557 
Acute parasagittal slices of 285μm thickness were prepared from the cerebella of 4- to 8-558 
week-old mutant and control littermates following published methods(1). In brief, brains 559 
were removed quickly and immersed in an ice-cold artificial cerebrospinal fluid (ACSF or 560 
extracellular) solution consisting of: 119 mM  NaCl, 26 mM NaHCO3, 11 mM glucose, 2.5 561 
mM KCl, 2.5 mM  CaCl2, 1.3 mM MgCl2 and 1 mM  NaH2PO4, pH 7.4 when gassed with 562 
5% CO2 / 95% O2. Cerebella were dissected and sectioned using a vibratome (Leica VT-563 
1000).  Slices were initially incubated at 35 °C for 35 min, and then at room temperature 564 
before recording in the same ACSF.  Dasatinib (200nM) was added during cerebellar 565 
sectioning and remained on the slices for recording. 566 
 567 
Recordings (SCA2 and Mtss1) 568 
Non-invasive extracellular recordings were obtained from Purkinje neurons in voltage-569 
clamp mode at 34.5 ± 1°C. The temperature was maintained using a dual channel 570 
heater controller (Model TC-344B, Warner Instruments) and slices were constantly 571 
perfused with carbogen-bubbled extracellular solution alone or with 200 nM dasatinib. 572 
Cells were visualized with an upright Leica microscope using a water-immersion 40× 573 
objective. Glass pipettes were pulled with Model P-1000 (Sutter instruments). Pipettes 574 
had 1 to 3 MΩ resistance when filled with extracellular solution and were used to record 575 
action potential-associated capacitative current transients near Purkinje neuron axon 576 
hillock with the pipette potential held at 0 mV. Data was acquired at 20 kHz using a 577 
Multiclamp 700B amplifier, Digidata 1440 with pClamp10 (Molecular Devices), filtered at 578 
4 kHz.  A total of 50 to 100 Purkinje neurons were measured from each genotype and 579 
each recording was of 2 minutes in duration. The experimenter was blinded to the 580 
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mouse genotype and 2 to 4 mice were used per genotype. Simultaneous mGluR EPSPs 581 
and calcium were measured in the presence of GABAA receptor antagonist, picrotoxin 582 
(PTX at 100 µM), AMPA receptor blockers (5 µM NBQX and 10 µM DNQX) using a two- 583 
photon microscope and a standard electrophysiology set-up. The patch pipettes had 4 to 584 
5 MΩ resistance when filled with internal solution (135 mM KMS04, NaCl, 10 mM 585 
HEPES, 3 mM MgATP, 0.3 mM Na2GTP) containing 200 µM Oregon Green Bapta1 and 586 
20 µM Alexa 594. The stimulating electrode was filled with ACSF containing 20 µM 587 
Alexa 594, placed in the dendritic region to minimally stimulate PF synaptic inputs. Slow 588 
mGluR EPSPs in control littermate and mutant were elicited by stimulation of PFs with 589 
100 Hz trains, and 10 pulses in the presence of receptor antagonists that block AMPA, 590 
NMDA, GABAA receptors. Corresponding intracellular Ca
2+ signals (ΔF/F) for responses 591 
for wild type and mutant mGluR EPSPs were blocked by the mGluR1 antagonist 592 
CPCCOET.  593 
 Experiments were analyzed using both the Clampfit and Igor algorithms, and 594 
were further analyzed using Microsoft Excel. Figures were made in Igor program. 595 
Calcium signals were analyzed using Slidebook (Intelligent Imaging Innovations, Inc.).  596 
Results are presented as mean ±SEM. All chemicals were purchased either from Sigma 597 
Aldrich, Tocris and Invitrogen, USA.)  598 
 599 
Biocytin fills of Purkinje neurons or Intracellular labeling of Purkinje neurons with  600 
Biocytin: 601 
Biocytin filling of Purkinje neurons was performed using recording pipettes filled with 1% 602 
Biocytin (Tocris). Purkinje neurons were filled for 15 to 30 minutes and then the pipette 603 
was removed slowly for enabling the cell membrane to reseal. Slices were then fixed in 604 
4% Paraformaldehyde overnight and washed 3 times with phosphate-buffered saline 605 
(PBS). Slices were then incubated with Alexa Fluor 488 streptavidin (1:500, Life S11223) 606 
in PBS, 0.5% Triton X-100, and 10% normal goat serum for 90min. After another 3 PBS 607 
washes, the slices were then mounted onto a slide with prolong gold. Individual biocytin-608 
filled Purkinje cells were visualized on a Leica SP2 AOBS laser scanning microscope at 609 
a 0.5um step size. Dendritic arbor volume was measured by calculating the biocytin-610 
filled area in each confocal optical section using ImageJ, adding the areas in each z-611 
stack, and multiplying by the step size. 612 
 613 
Ex-vivo Electrophysiology (SCA1) 614 
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Solutions 615 
Artificial CSF (aCSF) contained the following (in mM): 125 NaCl, 3.5 KCl, 26 NaHCO3, 616 
1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, and 10 glucose. For all recordings, pipettes were filled 617 
with internal recording solution containing the following (in mM): 119 K Gluconate, 2 Na 618 
gluconate, 6 NaCl, 2 MgCl2, 0.9 EGTA, 10 HEPES, 14 Tris-phosphocreatine, 4 MgATP, 619 
0.3 tris-GTP, pH 7.3, osmolarity 290 mOsm. 620 
 621 
Preparation of brain slices for electrophysiological recordings. 622 
Mice were anesthetized by isofluorane inhalation, decapitated, and the brains were 623 
submerged in pre-warmed (33°C) aCSF.  Slices were prepared in aCSF containing 624 
dasatinib or DMSO and held at 32.5-34°C on a VT1200 vibratome (Leica).  Slices were 625 
prepared to a thickness of 300 µm. Once slices were obtained, they were incubated in 626 
continuously carbogen (95% 02/5% CO2)-bubbled aCSF containing DMSO or dasatinib 627 
for 45 minutes at 33°C. Slices were subsequently stored in continuously carbon-bubbled 628 
aCSF containing DMSO or dasatinib at room temperature until use.  For recordings, 629 
slices were placed in a recording chamber and continuously perfused with carbogen-630 
bubbled ACSF containing DMSO or dasatinib at 33°C with a flow rate of 2–3 mls/min. 631 
 632 
Patch-clamp recordings 633 
Purkinje neurons were identified for patch-clamp recordings in parasagittal cerebellar 634 
slices using a 40x water-immersion objective and Eclipse FN1 upright microscope 635 
(Nikon) with infrared differential interference contrast (IR-DIC) optics that were visualized 636 
using NIS Elements image analysis software (Nikon). Borosilicate glass patch pipettes 637 
were pulled with resistances of 3–5 MΩ.  Recordings were made 5 hours after slice 638 
preparation.  Data were acquired using an Axon CV-7B headstage amplifier, Axon 639 
Multiclamp 700B amplifier, Digidata 1440A interface, and pClamp-10 software (MDS 640 
Analytical Technologies).  In all cases, acquired data were digitized at 100 kHz.  641 
 642 
 643 
QUANTIFICATION AND STATISTICAL ANALYSIS  644 
For cell counts, firing rates, rotorod and activity chamber 2-tailed non-homodidactic 645 
Student’s T-test was used to calculate significance.  646 
 647 
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For cerebellar dasatinib cohorts of 2-5 mice were tested. Analysis was T-test with two-648 
stage step-up method of Benjamini, Krieger and Yekutieli with a 1% FDR for 649 
multiple test correction. 650 
 651 
To compare firing rates and RNAIP 1-way ANOVA followed by Tukey post-hoc testing 652 
was used. Luciferase assay was evaluated using two-way ANOVA with reporter 653 
construct and co-transfected plasmids as independent variables. 654 
 655 
For electrophysiology 2-3 mice per condition were evaluated with investigator blinded to 656 
genotype. For MTSS1 rotorod and activity chamber cohorts of 10 age matched animals 657 
were examined with investigator blind to genotypes.  658 
 659 
For western blots and immune fluorescence 2-5 mice per genotype and age were 660 
evaluated. 661 
Author Contributions 662 
AEO and SXA conceived the project. ASB, SXA, BA, JM performed and 663 
interpreted most experiments. PM performed and interpreted all electrophysiology in 664 
Mtss1EX15 and ATXN2Q127 mice. EP and MJ performed and interpreted all 665 
electrophysiology and western blots in βIII-spectrin-/-  mice. RC, HH and VS performed 666 
and interpreted all electrophysiology and western blots in ATXN1Q82 mice. SP and DS 667 
performed and interpreted MTSS1 western blot and QPCR in ATNX2Q127 mice and HEK-668 
293 cell RNAIP. SP performed and interpreted MTSS1 staining in human samples. ET 669 
quantified biocytin-filled Purkinje data.  TSO and SMP contributed ideas and interpreted 670 
results. ASB and AEO wrote the manuscript with input from all authors. 671 
 672 
Acknowledgements 673 
The authors would like to acknowledge JoAnn Buchanan for assistance with TEM 674 
microscopy, Hak Kyun Kim, Miguel Mata, Peter Sarnow for assistance with ribosome 675 
profiling, and SBNFL for assistance with behavior assays. Funding: Oro R01 AR052785, 676 
Brown F32 GM105227, Otis R01 NS090930, Jackson The Wellcome Trust 093077   677 
 678 
References 679 
1. Hansen ST, Meera P, Otis TS, Pulst SM (2013) Changes in Purkinje cell firing and 680 
gene expression precede behavioral pathology in a mouse model of SCA2. 681 
Human Molecular Genetics 22(2):271–283. 682 
2. Inoue T, et al. (2001) Calcium dynamics and electrophysiological properties of 683 
MTSS1/SFK Ataxia  
 
22 of 32  
cerebellar Purkinje cells in SCA1 transgenic mice. J Neurophysiol 85(4):1750–684 
1760. 685 
3. Perkins EM, et al. (2010) Loss of  -III Spectrin Leads to Purkinje Cell Dysfunction 686 
Recapitulating the Behavior and Neuropathology of Spinocerebellar Ataxia Type 5 687 
in Humans. Journal of Neuroscience 30(14):4857–4867. 688 
4. Hourez R, et al. (2011) Aminopyridines Correct Early Dysfunction and Delay 689 
Neurodegeneration in a Mouse Model of Spinocerebellar Ataxia Type 1. Journal 690 
of Neuroscience 31(33):11795–11807. 691 
5. Dell'Orco JM, et al. (2015) Neuronal Atrophy Early in Degenerative Ataxia Is a 692 
Compensatory Mechanism to Regulate Membrane Excitability. J Neurosci 693 
35(32):11292–11307. 694 
6. Nakamura K, et al. (2001) SCA17, a novel autosomal dominant cerebellar ataxia 695 
caused by an expanded polyglutamine in TATA-binding protein. Human Molecular 696 
Genetics 10(14):1441–1448. 697 
7. Dansithong W, et al. (2015) Ataxin-2 Regulates RGS8 Translation in a New BAC-698 
SCA2 Transgenic Mouse Model. PLoS Genet 11(4):e1005182–29. 699 
8. Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K (2003) Ataxin-3 700 
Interactions with Rad23 and Valosin-Containing Protein and Its Associations with 701 
Ubiquitin Chains and the Proteasome Are Consistent with a Role in Ubiquitin-702 
Mediated Proteolysis. Molecular and Cellular Biology 23(18):6469–6483. 703 
9. Burnett B (2003) The polyglutamine neurodegenerative protein ataxin-3 binds 704 
polyubiquitylated proteins and has ubiquitin protease activity. Human Molecular 705 
Genetics 12(23):3195–3205. 706 
10. Iwaki A, et al. (2007) Heterozygous deletion of ITPR1, but not SUMF1, in 707 
spinocerebellar ataxia type 16. Journal of medical genetics 45(1):32–35. 708 
11. Marelli C, et al. (2011) SCA15 due to large ITPR1 deletions in a cohort of 333 709 
white families with dominant ataxia. Archives of neurology 68(5):637–643. 710 
12. Jackson M, et al. (2001) Modulation of the neuronal glutamate transporter EAAT4 711 
by two interacting proteins. Nature 410(6824):89–93. 712 
13. Ikeda Y, et al. (2006) Spectrin mutations cause spinocerebellar ataxia type 5. Nat 713 
Genet 38(2):184–190. 714 
14. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the 715 
c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4):693–702. 716 
15. Stein PL, Vogel H, Soriano P (1994) Combined deficiencies of Src, Fyn, and Yes 717 
tyrosine kinases in mutant mice. Genes & Development 8(17):1999–2007. 718 
16. Grant SG, et al. (1992) Impaired long-term potentiation, spatial learning, and 719 
hippocampal development in fyn mutant mice. Science 258(5090):1903–1910. 720 
MTSS1/SFK Ataxia  
 
23 of 32  
17. Grant SG, Karl KA, Kiebler MA, Kandel ER (1995) Focal adhesion kinase in the 721 
brain: novel subcellular localization and specific regulation by Fyn tyrosine kinase 722 
in mutant mice. Genes & Development 9(15):1909–1921. 723 
18. Kuo G (2005) Absence of Fyn and Src Causes a Reeler-Like Phenotype. Journal 724 
of Neuroscience 25(37):8578–8586. 725 
19. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H (1991) CSK: a 726 
protein-tyrosine kinase involved in regulation of src family kinases. Journal of 727 
Biological Chemistry 266(36):24249–24252. 728 
20. Zheng XM, Wang Y, Pallen CJ (1992) Cell transformation and activation of pp60c-729 
src by overexpression of a protein tyrosine phosphatase. Nature 359(6393):336–730 
339. 731 
21. Kapus A, Szászi K, Sun J, Rizoli S, Rotstein OD (1999) Cell shrinkage regulates 732 
Src kinases and induces tyrosine phosphorylation of cortactin, independent of the 733 
osmotic regulation of Na+/H+ exchangers. Journal of Biological Chemistry 734 
274(12):8093–8102. 735 
22. Lu YM, Roder JC, Davidow J, Salter MW (1998) Src activation in the induction of 736 
long-term potentiation in CA1 hippocampal neurons. Science 279(5355):1363–737 
1367. 738 
23. Imamura K, et al. (2017) The Src/c-Abl pathway is a potential therapeutic target in 739 
amyotrophic lateral sclerosis. Sci Transl Med 9(391):eaaf3962. 740 
24. Kaufman AC, et al. (2015) Fyn inhibition rescues established memory and 741 
synapse loss in Alzheimer mice. Ann Neurol 77(6):953–971. 742 
25. Pal R, et al. (2014) Src-dependent impairment of autophagy by oxidative stress in 743 
a mouse model of Duchenne muscular dystrophy. Nature Communications 5:1–744 
10. 745 
26. Lee Y-G, Macoska JA, Korenchuk S, Pienta KJ (2002) MIM, a Potential 746 
Metastasis Suppressor Gene in Bladder Cancer. Neoplasia 4(4):291–294. 747 
27. Yang C, Hoelzle M, Disanza A, Scita G, Svitkina T (2009) Coordination of 748 
Membrane and Actin Cytoskeleton Dynamics during Filopodia Protrusion. PLoS 749 
ONE 4(5):e5678–9. 750 
28. Bershteyn M, Atwood SX, Woo W-M, Li M, Oro AE (2010) MIM and Cortactin 751 
Antagonism Regulates Ciliogenesis and Hedgehog Signaling. 19(2):270–283. 752 
29. Quinones GA, Jin J, Oro AE (2010) I-BAR protein antagonism of endocytosis 753 
mediates directional sensing during guided cell migration. The Journal of Cell 754 
Biology 189(2):353–367. 755 
30. Callahan CA, et al. (2004) MIM/BEG4, a Sonic hedgehog-responsive gene that 756 
potentiates Gli-dependent transcription. Genes & Development 18(22):2724–757 
2729. 758 
MTSS1/SFK Ataxia  
 
24 of 32  
31. Ohnishi H, Murata Y, Okazawa H, Matozaki T (2011) Src family kinases: 759 
modulators of neurotransmitter receptor function and behavior. Trends in 760 
Neurosciences 34(12):629–637. 761 
32. Uruno T, et al. (2001) Activation of Arp2/3 complex-mediated actin polymerization 762 
by cortactin. Nat Cell Biol 3(3):259–266. 763 
33. Wu H, Parsons JT (1993) Cortactin, an 80/85-kilodalton pp60src substrate, is a 764 
filamentous actin-binding protein enriched in the cell cortex. The Journal of Cell 765 
Biology 120(6):1417–1426. 766 
34. Huang C, et al. (1997) Down-regulation of the filamentous actin cross-linking 767 
activity of cortactin by Src-mediated tyrosine phosphorylation. Journal of 768 
Biological Chemistry 272(21):13911–13915. 769 
35. Lynch DK, et al. (2003) A Cortactin-CD2-associated Protein (CD2AP) Complex 770 
Provides a Novel Link between Epidermal Growth Factor Receptor Endocytosis 771 
and the Actin Cytoskeleton. Journal of Biological Chemistry 278(24):21805–772 
21813. 773 
36. Hensel N, Claus P (2018) The Actin Cytoskeleton in SMA and ALS: How Does It 774 
Contribute to Motoneuron Degeneration? The Neuroscientist 24(1):54–72. 775 
37. Yan Z, Kim E, Datta D, Lewis DA, Soderling SH (2016) Synaptic Actin 776 
Dysregulation, a Convergent Mechanism of Mental Disorders? Journal of 777 
Neuroscience 36(45):11411–11417. 778 
38. Avery AW, Thomas DD, Hays TS (2017) β-III-spectrin spinocerebellar ataxia type 779 
5 mutation reveals a dominant cytoskeletal mechanism that underlies dendritic 780 
arborization. Proceedings of the National Academy of Sciences 114(44):E9376–781 
E9385. 782 
39. Yu D, et al. (2011) Mice deficient in MIM expression are predisposed to 783 
lymphomagenesis. 31(30):3561–3568. 784 
40. Saarikangas J, et al. (2011) Missing-in-metastasis MIM/MTSS1 promotes actin 785 
assembly at intercellular junctions and is required for integrity of kidney epithelia. 786 
Journal of Cell Science 124(8):1245–1255. 787 
41. Saarikangas J, et al. (2015) MIM-Induced Membrane Bending Promotes Dendritic 788 
Spine Initiation. Developmental Cell:1–17. 789 
42. Glassmann A, et al. (2007) Developmental expression and differentiation-related 790 
neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and 791 
transformed cerebellar cells. BMC Dev Biol 7(1):111–15. 792 
43. Nixdorf S, et al. (2004) Expression and regulation of MIM (Missing In Metastasis), 793 
a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell 794 
lines. Cancer Letters 215(2):209–220. 795 
44. Sistig T (2017) Mtss1 promotes maturation and maintenance of cerebellar 796 
MTSS1/SFK Ataxia  
 
25 of 32  
neurons via splice variant-specific effects. Brain Structure and Function 0(0):0–0. 797 
45. Fahrenkamp D, Herrmann O, Koschmieder S, Brummendorf TH, Schemionek M 798 
(2017) Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein 799 
depletion. Nature Publishing Group:1–3. 800 
46. Guyenet SJ, et al. (2010) A Simple Composite Phenotype Scoring System for 801 
Evaluating Mouse Models of Cerebellar Ataxia. JoVE (39):1–3. 802 
47. Dawson JC, Timpson P, Kalna G, Machesky LM (2011) Mtss1 regulates 803 
epidermal growth factor signaling in head and neck squamous carcinoma cells. 804 
31(14):1781–1793. 805 
48. Hara T, et al. (2006) Suppression of basal autophagy in neural cells causes 806 
neurodegenerative disease in mice. Nature 441(7095):885–889. 807 
49. Komatsu M, et al. (2006) Loss of autophagy in the central nervous system causes 808 
neurodegeneration in mice. Nature 441(7095):880–884. 809 
50. Kegel KB, et al. (2000) Huntingtin expression stimulates endosomal-lysosomal 810 
activity, endosome tubulation, and autophagy. J Neurosci 20(19):7268–7278. 811 
51. Nixon RA, et al. (2005) Extensive involvement of autophagy in Alzheimer disease: 812 
an immuno-electron microscopy study. Journal of Neuropathology and 813 
Experimental Neurology 64(2):113–122. 814 
52. Nascimento-Ferreira I, et al. (2011) Overexpression of the autophagic beclin-1 815 
protein clears mutant ataxin-3 and alleviates Machado–Joseph disease. Brain 816 
134(5):1400–1415. 817 
53. Ropolo A, et al. (2007) The pancreatitis-induced vacuole membrane protein 1 818 
triggers autophagy in mammalian cells. Journal of Biological Chemistry 819 
282(51):37124–37133. 820 
54. Gal J, Ström A-L, Kilty R, Zhang F, Zhu H (2007) p62 Accumulates and Enhances 821 
Aggregate Formation in Model Systems of Familial Amyotrophic Lateral Sclerosis. 822 
Journal of Biological Chemistry 282(15):11068–11077. 823 
55. Shakkottai VG, et al. (2011) Early Changes in Cerebellar Physiology Accompany 824 
Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3. 825 
Journal of Neuroscience 31(36):13002–13014. 826 
56. Canepari M, Ogden D (2003) Evidence for protein tyrosine phosphatase, tyrosine 827 
kinase, and G-protein regulation of the parallel fiber metabotropic slow EPSC of 828 
rat cerebellar Purkinje neurons. J Neurosci 23(10):4066–4071. 829 
57. Walter JT, Alviña K, Womack MD, Chevez C, Khodakhah K (2006) Decreases in 830 
the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. 831 
Nat Neurosci 9(3):389–397. 832 
58. Cerminara NL, Rawson JA (2004) Evidence that climbing fibers control an intrinsic 833 
MTSS1/SFK Ataxia  
 
26 of 32  
spike generator in cerebellar Purkinje cells. J Neurosci 24(19):4510–4517. 834 
59. Womack M, Khodakhah K (2002) Active contribution of dendrites to the tonic and 835 
trimodal patterns of activity in cerebellar Purkinje neurons. J Neurosci 836 
22(24):10603–10612. 837 
60. Meera P, Pulst S, Otis T (2017) A positive feedback loop linking enhanced mGluR 838 
function and basal calcium in spinocerebellar ataxia type 2. Elife 6:19854. 839 
61. Porkka K, et al. (2008) Dasatinib crosses the blood-brain barrier and is an efficient 840 
therapy for central nervous system Philadelphia chromosome-positive leukemia. 841 
Blood 112(4):1005–1012. 842 
62. Pulst SM, et al. (1996) Moderate expansion of a normally biallelic trinucleotide 843 
repeat in spinocerebellar ataxia type 2. Nat Genet 14(3):269–276. 844 
63. Huynh DP, Maalouf M, Silva AJ, Schweizer FE, Pulst SM (2009) Dissociated fear 845 
and spatial learning in mice with deficiency of ataxin-2. PLoS ONE 4(7):e6235. 846 
64. Elden AC, et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions 847 
are associated with increased risk for ALS. Nature 466(7310):1069–1075. 848 
65. Lim C, Allada R (2013) ATAXIN-2 Activates PERIOD Translation to Sustain 849 
Circadian Rhythms in Drosophila. Science 340(6134):875–879. 850 
66. Xu X, et al. (2014) Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and 851 
Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice. Molecular 852 
Cancer Therapeutics 13(7):1729–1739. 853 
67. Wu W, et al. (2014) MicroRNA-135b regulates metastasis suppressor 1 854 
expression and promotes migration and invasion in colorectal cancer. Mol Cell 855 
Biochem 388(1-2):249–259. 856 
68. Zhou W, et al. (2012) MiR-135a promotes growth and invasion of colorectal 857 
cancer via metastasis suppressor 1 in vitro. Acta biochimica et biophysica Sinica 858 
44(10):838–846. 859 
69. Kedmi M, et al. (2015) EGF induces microRNAs that target suppressors of cell 860 
migration: miR-15b targets MTSS1 in breast cancer. Science Signaling 861 
8(368):ra29–ra29. 862 
70. Jahid S, et al. (2012) miR-23a Promotes the Transition from Indolent to Invasive 863 
Colorectal Cancer. Cancer Discovery 2(6):540–553. 864 
71. Orr HT, et al. (1993) Expansion of an unstable trinucleotide CAG repeat in 865 
spinocerebellar ataxia type 1. Nat Genet 4(3):221–226. 866 
72. Lam YC, et al. (2006) ATAXIN-1 Interacts with the Repressor Capicua in Its 867 
Native Complex to Cause SCA1 Neuropathology. Cell 127(7):1335–1347. 868 
73. Ingram M, et al. (2016) Cerebellar Transcriptome Profiles of ATXN1 Transgenic 869 
MTSS1/SFK Ataxia  
 
27 of 32  
Mice Reveal SCA1 Disease Progression and Protection Pathways. Neuron 870 
89(6):1194–1207. 871 
74. Lise S, et al. (2012) Recessive Mutations in SPTBN2 Implicate β-III Spectrin in 872 
Both Cognitive and Motor Development. PLoS Genet 8(12):e1003074–14. 873 
75. Burright EN, et al. (1995) SCA1 transgenic mice: a model for neurodegeneration 874 
caused by an expanded CAG trinucleotide repeat. Cell 82(6):937–948. 875 
76. Gonzalez-Quevedo R, Shoffer M, Horng L, Oro AE (2005) Receptor tyrosine 876 
phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive 877 
gene MIM/BEG4. The Journal of Cell Biology 168(3):453–463. 878 
77. Alazami AM, et al. (2015) Accelerating Novel Candidate Gene Discovery in 879 
Neurogenetic Disorders via Whole-Exome Sequencing of Prescreened Multiplex 880 
Consanguineous Families. CellReports 10(2):148–161. 881 
78. Gennarino VA, et al. (2015) Pumilio1 Haploinsufficiency Leads to SCA1-like 882 
Neurodegeneration by Increasing Wild-Type Ataxin1 Levels. Cell 160(6):1087–883 
1098. 884 
79. Gennarino VA, et al. (2018) A Mild PUM1 Mutation Is Associated with Adult- 885 
Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and 886 
Seizures. Cell 172(5):924–932.e11. 887 
80. Chen D, et al. (2012) Pumilio 1 Suppresses Multiple Activators of p53 to 888 
Safeguard Spermatogenesis. Current Biology 22(5):420–425. 889 
81. Kedde M, et al. (2010) A Pumilio-induced RNA structure switch in p27-3′ UTR 890 
controls miR-221 and miR-222 accessibility. Nature Publishing Group 891 
12(10):1014–1020. 892 
82. Lei R, et al. (2013) Suppression of MIM by microRNA-182 activates RhoA and 893 
promotes breast cancer metastasis. 33(10):1287–1296. 894 
83. Wang Y, Arribas-Layton M, Chen Y, Lykke-Andersen J, Sen GL (2015) DDX6 895 
Orchestrates Mammalian Progenitor Function through the mRNA Degradation 896 
and Translation Pathways. Molecular Cell 60(1):118–130. 897 
84. Li C, Götz J (2017) Somatodendritic accumulation of Tau in Alzheimer's disease 898 
is promoted by Fyn‐ mediated local protein translation. The EMBO Journal 899 
36(21):3120–3138. 900 
85. Pal R, et al. (2014) Src-dependent impairment of autophagy by oxidative stress in 901 
a mouse model of Duchenne muscular dystrophy. Nature Communications 5:1–902 
10. 903 
86. Park J, et al. (2013) RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels 904 
and toxicity in SCA1. Nature Publishing Group 498(7454):325–331. 905 
87. Rodríguez CI, et al. (2000) High-efficiency deleter mice show that FLPe is an 906 
MTSS1/SFK Ataxia  
 
28 of 32  
alternative to Cre-loxP. Nat Genet 25(2):139–140. 907 
88. Tang S-HE, Silva FJ, Tsark WMK, Mann JR (2002) A cre/loxP-deleter transgenic 908 
line in mouse strain 129S1/SvImJ. genesis 32(3):199–202. 909 
89. Zhang X-M, et al. (2004) Highly restricted expression of Cre recombinase in 910 
cerebellar Purkinje cells. genesis 40(1):45–51. 911 
 912 
 913 
Figure Legends 914 
Figure 1.     MIMEX15 mutants develop progressive spinocerebellar ataxia 915 
A: The structure of the Mtss1 locus with alternative promoters and Src interacting 916 
domain deleted in MIMEX15 mutants. B: Loss of MTSS1 protein in MIMEX15 cerebellum 917 
lysate shown with MTSS1 antibody against N-terminal IMD domain. C,D MIMEX15 show 918 
slower movement velocity and reduced rearing frequency in open field tests. E: Impaired 919 
rotarod performance in MIMEX15 mutants shown as reduced duration (time to fall). F: A 920 
composite test of gait, balance, and grip strength to measure spinocerebellar ataxia 921 
symptoms. Increased score reflects reduced function with an age dependent increase in 922 
severity in MIMEX15 mutants. G: Age dependent loss of Purkinje neurons in MIMEX15 923 
mutants occurs after the onset of ataxia.  H: At 20 weeks MIMLoxp/-;Pcp2-Cre and 924 
MIMLoxp/Loxp;Pcp2-Cre mutants show dramatic reduction in Purkinje neurons that stain 925 
with MTSS1. Many Purkinje neurons persist, as there is a less dramatic reduction in 926 
calbindin positive Purkinje cell number. *p<0.05, **p<0.005, ***p<5E-5,  one-way 927 
ANOVA with Tukey post-hoc test. ns not significant. Error bars, s.e.m.  928 
 929 
Figure 2.    MIMEX15 mutant Purkinje neurons undergo autophagy 930 
A: MIMEX15 mutants display fused mitochondria shown by increased Complex 5 ATP-931 
synthase immuno-staining and collapsed Golgi shown by reduced Giantin immune-932 
staining at 4 weeks. B: 8 week old MIMEX15 mutants show increased LC3-II abundance 933 
(*P<0.005 student’s t-test) , C: MIMEX15 mutants show increased levels of mRNA for the 934 
autophagocytic marker  VMP1 (*p<0.05 student’s t-test).  D: MIMEX15 mutants show 935 
increased microglial infiltration shown by Aif1 transcript. E:  MIMEX15 mutants show 936 
GFAP+ glial infiltration during disease progression. F: Western blots quantifying 937 
increased cerebellar GFAP. G: MIMEX15 mutant cerebella do not have increased TUNEL 938 
stain at 4, 8 or 16 weeks of age. 939 
 940 
Figure 3.   Mtss1 prevents SFK dependent firing defects and ataxia 941 
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A:  Confocal projection of an individual Purkinje cell filled with biocytin and with 942 
fluorescent dye to visualize morphology (50μm, 5μm, 1μm scale bars). B: Measurement 943 
of dye filled Purkinje neurons show MIMEX15 mutants have reduced arbor volume (n=3 944 
each genotype), C: reduced dendritic spine density, but D: no change in dendritic spine 945 
length and E: no change in dendritic spine width (MIMEX15/+ n=3, 1720 spines; MIMEX15 946 
n=3, 1454 spines, *p<0.05 student’s t-test). Error bars, s.e.m  F: Western blot for active 947 
SFK-Y416 phosphorylation with actin loading control. Cerebellar lysate from MIMEX15 and 948 
age matched controls collected at indicated times between post-natal day 15 (P15) and 949 
post-natal day 30 (P30). G: Slow excitatory post synaptic potential (EPSP) spikes in wild 950 
type (WT) and MIMEX15 (top) elicited by stimulation of parallel fibers with 10 pulse trains 951 
at 100 Hz in the presence AMPA, NMDA and GABA receptor antagonists (control 952 
conditions). Corresponding intra-cellular Ca2+ signals (ΔF/F) for responses for WT and 953 
MIMEX15 mGluR EPSPs are illustrated. EPSPs and corresponding Ca2+ signals are 954 
blocked by mGluR1 antagonist CPCCOEt (bottom). Summary data of intracellular Ca2+ 955 
signals (ΔF/F) for responses for WT and MTSS1EX15 in control conditions and in 956 
presence of  CPCCOEt are shown (right). H: Percent histograms of Purkinje neuron 957 
mean firing frequencies (left), examples of extracellular recording of 1 second duration of 958 
a spontaneously spiking Purkinje neuron in respective condition (center), and histograms 959 
of inter-spike intervals calculated for the 2 minute recording periods of the same neuron 960 
(right) are shown for WT, MIMEX15, WT+dasatinib, or MIMEX15+dasatinib conditions. I:  961 
Summary of data presented in H *p=6.1E-14 **p=1E-13, one-way ANOVA, Tukey post-962 
hoc J: Direct cerebellar administration of dasatinib maintains rotarod performance, 963 
slowing the progressive ataxia in MIMEX15 mice. q=0.006, two-stage step-up Benjamini, 964 
Krieger, Yekutieli method, Error bars, s.e.m.  965 
 966 
Figure 4.    MTSS1 is an Atxn2 translation target 967 
A: Western blot of 24-week whole cerebellum lysate shows 90% reduction of upper 968 
band (arrow) that corresponds MTSS1 in ATXN2Q127 mice, while calbindin was reduced 969 
50%. Actin is included as a loading control *p<0.01, **p<0.001, Student’s t-test. B: 970 
Western blot for active SFK-Y416 phosphorylation and total Src, with tubulin loading 971 
control using cerebellar lysate from 24 week Atxn2Q127 mice show 8-fold increase in 972 
SFK-Y416 abundance. C: Percent histograms of Purkinje neuron mean firing frequ-973 
encies (left), examples of extracellular recording of 1 second duration of a spontaneously 974 
spiking Purkinje neuron in respective condition (center), and histograms of inter-spike 975 
intervals calculated for the 2 minute recording periods of the same neuron for ATXN2Q127 976 
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and ATXN2Q127+dasatinib D: Mean firing rates **p=3.77E-8, one-way ANOVA, Tukey 977 
post-hoc E: Western blot for Atxn2 with tubulin loading control. Cerebellar lysate from 4-978 
week old MIMEX15 cerebellum and age matched controls. F: RNA-IP in HEK-293 cells for 979 
flag-ATXN2Q22 and flag-ATXN2Q108 show enrichment for MTSS1 but not GAPDH mRNA, 980 
error bars are SD. G: Polyribosome fractionation in 293T cells transfected with MTSS1-981 
UTR reporter and pCDNA, ATXN2Q22, ATXN2Q108, or ATXN2Q22+ATXN2Q108. Green line 982 
indicates UV254nm absorbance (nucleic acids) with 40S, 60S, 80S, polyribosome peaks 983 
labeled. H: Remaining Purkinje neurons in human SCA2 cerebellum (Atxn2Q22/Q41) show 984 
reduced MTSS1 staining compared to age matched control (Atxn2Q22/Q22).  985 
 986 
Figure 5.   SFK dysregulation occurs in multiple SCA 987 
A: Western blot of 15-week whole cerebellum lysate shows 95% reduction of upper 988 
band that corresponds MTSS1 in ATXN1Q82 mice with only a 50% reduction in calbindin. 989 
Tubulin is included as a loading control. B: Western blot of 4-week old MIMEX15 990 
cerebellum lysate shows no change in phospho-Serine776 ATXN1 levels. C: RNA-seq 991 
from ATXN1Q82 cerebella show reduced FPKM for Mtss1 mRNA in 12 and 28 week 992 
samples, * q<0.005. D: Mean firing frequency values in Hz for WT and ATXN1Q82 mice, 993 
with and without dasatinib treatment. Error bars, s.e.m. (*p=0.0094, one-way ANOVA 994 
with Tukey post-hoc) E: Western blot of 3-week whole cerebellum lysate shows no 995 
change MTSS1 in βIII-spectrin-/-  mice, yet active SFK-Y416 phosphorylation is 996 
increased. Calbindin and total Src are included as a loading controls. F: SPTNB2 997 
abundance is not changed in 4-week old MIMEX15 mice. G: βIII-spectrin levels are 998 
reduced 40% in 24-week ATXN2Q127 mice. H: Mean firing frequency values in Hz for WT 999 
and βIII-spectrin-/- mice, with and without dasatinib treatment. Error bars, s.e.m. (*p<0.05, 1000 
1-way ANOVA, Tukey posthoc ) I: A model where pathogenic alleles of ATNX1 1001 
(ATXN1Q82) and ATXN2 (ATXN2Q42) prevent the accumulation of MTSS1 and SPTBN2 1002 
which restrain SFK activity to prevent abnormal firing patterns and neurodegeneration. 1003 
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